126 related articles for article (PubMed ID: 7328842)
21. Elevated plasma ammonia level in hepatic cirrhosis: role of glucagon.
Kabadi UM; Eisenstein AB; Konda J
Gastroenterology; 1985 Mar; 88(3):750-6. PubMed ID: 3881308
[TBL] [Abstract][Full Text] [Related]
22. Insulin, C-peptide and glucagon levels during OGTT in hepatic cirrhosis and in patients with prehepatic block.
Gerö L; Korányi L; Szalay F; Büki B; Tamás G
Acta Diabetol Lat; 1982; 19(1):55-64. PubMed ID: 7041501
[TBL] [Abstract][Full Text] [Related]
23. Effects of transjugular intrahepatic portasystemic shunt (TIPS) on splanchnic and systemic hemodynamics, and hepatic function in patients with portal hypertension. Preliminary results.
Rodríguez-Laiz JM; Bañares R; Echenagusia A; Casado M; Camuñez F; Pérez-Roldán F; de Diego A; Cos E; Clemente G
Dig Dis Sci; 1995 Oct; 40(10):2121-7. PubMed ID: 7587778
[TBL] [Abstract][Full Text] [Related]
24. Pancreatic glucoregulatory hormones in cirrhosis of the liver: portal vein concentrations during intravenous glucose tolerance test and in response to a meal.
Holst JJ; Burcharth F; Kühl C
Diabete Metab; 1980 Jun; 6(2):117-27. PubMed ID: 6997101
[TBL] [Abstract][Full Text] [Related]
25. Hyperglucagonemia in liver cirrhosis with portal-systemic venous anastomoses: responses of plasma glucagon and gastric inhibitory polypeptide to oral or intravenous glucose in cirrhotics with normal or elevated fasting plasma glucose levels.
McDonald TJ; Dupre J; Caussignac Y; Radziuk J; Van Vliet S
Metabolism; 1979 Apr; 28(4):300-7. PubMed ID: 449682
[TBL] [Abstract][Full Text] [Related]
26. [Plasma level of glucagon in cirrhotic patients with portal hypertension during operation of portacaval shunts].
Feng H; Zhang Z; Leng X; Li S; Zhu J; Du R
Zhonghua Wai Ke Za Zhi; 1999 Apr; 37(4):222-4. PubMed ID: 11829825
[TBL] [Abstract][Full Text] [Related]
27. Plasma glucagon concentration in cirrhosis is related to liver function but not to portal-systemic shunting, systemic vascular resistance, or urinary sodium excretion.
Lewis FW; Adair O; Hossack KF; Everson GT; White JC; Rector WG
J Lab Clin Med; 1991 Jan; 117(1):67-75. PubMed ID: 1987311
[TBL] [Abstract][Full Text] [Related]
28. [Surgical treatment of portal hypertension in patients with bilharziosis and Banti's syndrome in tropical Africa (author's transl)].
Cornet L; Loubiere R; N'Guessan AH; Mobiot LM; Schaub VN; Kadio R; Acquaviva P
Chirurgie; 1980; 106(5):335-42. PubMed ID: 7418333
[No Abstract] [Full Text] [Related]
29. [Plasma glucagon responses to L-arginine in various diseases (author's transl)].
Morita N; Hayakawa H; Kawai K
Radioisotopes; 1978 Apr; 27(4):183-7. PubMed ID: 663316
[No Abstract] [Full Text] [Related]
30. Effect of portosystemic shunting on PGI2 and glucagon levels in humans.
Sitzmann JV; Campbell KA; Wu Y; Cameron JL
Ann Surg; 1993 Mar; 217(3):248-52. PubMed ID: 8452403
[TBL] [Abstract][Full Text] [Related]
31. Theoretical and practical considerations in the treatment of portal hypertension secondary to hepatic cirrhosis.
Bizer LS
Am Surg; 1984 Oct; 50(10):524-9. PubMed ID: 6385791
[TBL] [Abstract][Full Text] [Related]
32. [Glucagon test in cirrhosis of the liver (author's transl)].
Kurocka J; Spanár E; Levcík A; Záhradný V; Holan J
Cesk Gastroenterol Vyz; 1977 Jan; 31(1):36-41. PubMed ID: 852010
[No Abstract] [Full Text] [Related]
33. Glucagon in portal hypertension.
Pak JM; Lee SS
J Hepatol; 1994 Jun; 20(6):825-32. PubMed ID: 7930485
[No Abstract] [Full Text] [Related]
34. [Circulating types of human glucagon (author's transl)].
Valverde I
MMW Munch Med Wochenschr; 1978 Mar; 120(12):407-9. PubMed ID: 306029
[TBL] [Abstract][Full Text] [Related]
35. Disappearance of hepatic encephalopathy and improvement of liver function after surgical treatment of portal-systemic shunt in a patient with liver cirrhosis.
Moriya K; Kojima H; Matsumura M; Sakurai S; Imazu H; Uemura M; Honda H; Fukui H
Hepatogastroenterology; 2003; 50(52):1128-32. PubMed ID: 12845996
[TBL] [Abstract][Full Text] [Related]
36. [Effect of glucagon on plasma levels of 3',5'-adenosine monophosphate in patients with liver cirrhosis (author's transl)].
Malinovská V; Rysánek K; Bílková B; Martínek K; Ochmanová D
Cas Lek Cesk; 1977 Jul; 116(27):850-3. PubMed ID: 198133
[No Abstract] [Full Text] [Related]
37. [Effect of glucagon on glucose and nonesterified fatty acids in chronic hepatic disease (author's transl)].
Malinovská V; Holík K
Cas Lek Cesk; 1974 Feb; 113(8):245-7. PubMed ID: 4434446
[No Abstract] [Full Text] [Related]
38. Low serum T3 and raised reverse T3 levels in hepatic cirrhosis: role of glucagon.
Kabadi UM; Kabadi MU; Premachandra BN
Am J Gastroenterol; 1991 Oct; 86(10):1504-7. PubMed ID: 1928046
[TBL] [Abstract][Full Text] [Related]
39. [Lymph vessel system and liver: functional and pathophysiological relationship (author's transl)].
Földi M
Leber Magen Darm; 1974 Oct; 4(6):274-9. PubMed ID: 4437263
[No Abstract] [Full Text] [Related]
40. Hepatic and renal metabolism before and after portasystemic shunts in patients with cirrhosis.
Owen OE; Mozzoli MA; Reichle FA; Kreulen TH; Owen RS; Boden G; Polansky M
J Clin Invest; 1985 Sep; 76(3):1209-17. PubMed ID: 4044831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
